A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.

Ghassan K. Abou-Alfa,Stephen Lam Chan,Junji Furuse,Peter R. Galle,Robin Kate Kelley,Shukui Qin,Jon Armstrong,Annie Darilay,Gordana Vlahovic,Alejandra Negro,Bruno Sangro

A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.

2018

Ghassan K. Abou-Alfa
Stephen Lam Chan
Junji Furuse
Peter R. Galle
Robin Kate Kelley
Shukui Qin
Jon Armstrong
Annie Darilay
Gordana Vlahovic
Alejandra Negro
Bruno Sangro

TPS4144Background: Thus far, sorafenib remains the standard of care for first line systemic therapy in patients with advanced HCC but patient prognosis and quality of life (QOL) continues to be poo...

Keywords:

Hepatocellular carcinoma
Oncology
Phases of clinical research
Sorafenib
Systemic therapy
Pathology
Durvalumab
Medicine
Quality of life
Internal medicine
Tremelimumab
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations